Skip to main content
. 2018 Feb 9;11(3):361–369. doi: 10.1007/s40271-018-0297-5
Patient preferences can be indicators of treatment success and quality.
The golimumab GO-SAVE trial employed active surveillance to comparatively examine patient satisfaction among biologic products in rheumatoid arthritis (RA).
Most patients with RA who transitioned to golimumab from adalimumab or etanercept were satisfied with their overall golimumab experience.